Our BioSpherix Division is dedicated to research and product development for innovations in the biotechnology industry. Spherix is currently running a Phase 3 clinical trial to study the use of Naturlose® as a treatment for Type 2 diabetes. Among its other features, Naturlose® has been shown able to blunt the glucose spikes that impact diabetics after meals. If the Phase 3 trial establishes that Naturlose® is an effective treatment, Spherix will prepare a New Drug Application (NDA) for presentation to the Food and Drug Administration (FDA). FDA approval would give Spherix the right to market Naturlose® as a diabetes drug. Naturlose® has already been shown to be safe. Our facilities include laboratory and research areas specially designed to meet the specific areas of emphasis of our research partners and customers with a focus toward improving technologies for health and the environment.